• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

byMinjee Kim
February 10, 2022
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with acute myocardial infarction, Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes compared to patients receiving ramipril.

2. In patients with acute myocardial infarction, treatment with sacubitril-valsartan did not result in significantly lower rates of incident heart failure than did treatment with ramipril.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In the management of acute myocardial infarction, angiotensin-converting enzyme (ACE) inhibitors are often used to reduce the risk of fatal cardiovascular events and heart failure. Sacubitril-valsartan has been proposed as a new treatment for the management of myocardial infarction, as it has been shown to reduce the risk of clinical deterioration in the setting of heart failure. There is a gap in knowledge as to understanding the effect of Sacubitril-valsartan in patients with acute myocardial infarction. This study found that treatment with sacubitril-valsartan did not result in a significantly lower risk of death from cardiovascular causes or incident heart failure than did treatment with ramipril. This study was limited by patients discontinuing their assigned medications due to hypotension and cough. Nevertheless, these study’s findings are significant, as they demonstrate that sacubitril-valsartan is not more effective than ramipril in preventing incident heart failure or death from cardiovascular causes in patients post-myocardial infarction.

Click to read the study in NEJM

Relevant Reading: Drawing Boundaries around PARADISE

RELATED REPORTS

Dapagliflozin efficacious and safe in treating heart failure

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

In-Depth [randomized control trial]: This randomized control trial included 5661 patients; 2830 in the sacubitril-valsartan treatment group and 2831 in the ramipril treatment group. Patients without a history of heart failure were eligible if they had a myocardial infarction within 0.5 to 7 days before presentation. Patients who displayed clinical instability, eGFR < 30 ml/min, serum potassium greater than 5.2 mmol/liter, or an inability to take an ACE inhibitor or ARB were excluded from the study. The primary outcomes measured were death from cardiovascular causes or incident heart failure, including hospitalization for heart failure and outpatient episodes of symptomatic heart failure. Outcomes in the primary analysis were assessed via Cox proportional hazards regression model. Between the two treatment groups, death from cardiovascular causes occurred in 10.9% of patients in the sacubitril-valsartan group and 11.8% of patients in the ramipril group (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.78 to 1.07). Episodes of heart failure occurred in 11.9% of patients in the sacubitril-valsartan group and 13.2% of patients in the ramipril group (HR, 0.90; 95% CI, 0.78 to 1.04). Overall, this study determined that there was no significant benefit of sacubitril-valsartan compared to ramipril with respect to measured primary outcomes of death from cardiovascular causes or incident heart failure in the management of post-myocardial infarction patients.

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: ACE inhibitorsaceiacute myocardial infarctionEntrestoheart failuremyocardial infarctionramiprilsacubitril-valsartan
Previous Post

Significant morbidity among children observed following reintroduction of high-powered magnets into US market

Next Post

#VisualAbstract: Dutasteride 0.5mg daily has the highest probability of being the most efficacious treatment for male androgenetic alopecia

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin efficacious and safe in treating heart failure

May 13, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
Nonpowder gun-related pediatric eye injuries on the rise
Cardiology

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

April 22, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
Next Post
#VisualAbstract: Dutasteride 0.5mg daily has the highest probability of being the most efficacious treatment for male androgenetic alopecia

#VisualAbstract: Dutasteride 0.5mg daily has the highest probability of being the most efficacious treatment for male androgenetic alopecia

Quick Take: Efficacy of prehospital criteria in identifying trauma patients susceptible to undertriage

Mobile stroke units associated with better outcomes for acute ischemic stroke management

The spiritual history may improve the quality of the doctor-patient relationship

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.